KRAS and familial pancreatic carcinoma: Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRAS&lt;sup&gt;G12D&lt;/sup&gt;-mutated pancreatic cancer.